

**PB 11 of 2025**

National Health (Minimum Stockholding) Amendment Determination (No. 1) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 January 2025

Rebecca Richardson

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments commencing 1 February 2025 2

National Health (Minimum Stockholding) Determination 2023 2

Schedule 2—Amendments commencing 1 April 2025 7

National Health (Minimum Stockholding) Determination 2023 7

Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024* – 1 April 2025 8

National Health (Minimum Stockholding) Determination 2023 8

1 Name

 (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 1) 2025*.

 (2) This instrument may also be cited as PB 11 of 2025.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 February 2025. | 1 February 2025 |
| 2. Schedule 1 | 1 February 2025. | 1 February 2025 |
| 3. Schedule 2 | 1 April 2025. | 1 April 2025 |
| 4. Schedule 3 | Immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024*. | 1 April 2025 |

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 February 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the Eye | Refresh Liquigel | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the Eye | Refresh Tears Plus | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |
| Carmellose with glycerin | Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL | Application to the Eye | Optive | between 1 October 2024 and 31 January 2025—0 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glucose and ketone indicator‑urine | Test strips, 50 (Keto‑Diastix) | For External Use | Keto‑Diastix | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glyceryl trinitrate | Transdermal patch 36 mg | Transdermal | Minitran 10 | between 1 February 2025 and 30 September 2025—0 months stock by reference to usual demand |
| Glyceryl trinitrate | Transdermal patch 54 mg | Transdermal | Minitran 15 | between 1 February 2025 and 31 December 2025—0 months stock by reference to usual demand |

3 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | APO-Levetiracetam | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Keppra | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Kerron | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Levetiracetam GH | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral | Levetiracetam-AFT | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | APO-Levetiracetam | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Keppra | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Kevtam 1000 | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Levactam | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam GH | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam Mylan | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam SZ | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Levetiracetam Viatris | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | Levi 1000 | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |
| Levetiracetam | Tablet 1 g | Oral | NOUMED LEVETIRACETAM | between 1 August 2024 and 31 January 2025—4 months stock by reference to usual demand.  |

4 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Mirtazapine | Tablet 45 mg | Oral | NOUMED MIRTAZAPINE | between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand |

5 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | Ondansetron ODT Viatris | after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together |
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | after 31 May 2025—6 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together |
| Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | after 31 May 2025—4 months stock by reference to usual demand of both Ondansetron Tablets Viatris and Ondansetron Mylan Tablets added together |

6 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pioglitazone | Tablet 45 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | 4 months stock by reference to usual demand of both APOTEX-Pioglitazone and ARX-PIOGLITAZONE added together |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Piroxicam | Dispersible tablet 20 mg | Oral | Feldene-D | between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand |
| Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the Eye | Optix | between 1 February 2025 and 30 April 2025—0 months stock by reference to usual demand |

7 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril with felodipine | Tablet 2.5 mg‑2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Ramipril with felodipine | Tablet 2.5 mg-2.5 mg (modified release) | Oral | Triasyn 2.5/2.5 | between 1 February 2025 and 30 September 2025—0 months stock by reference to usual PBS demand |

8 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Telmisartan | Tablet 40 mg | Oral | NOUMED TELMISARTAN | between 1 December 2024 and 31 January 2025—0 months stock by reference to usual demand |

9 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trandolapril | Capsule 500 micrograms | Oral | Dolapril 0.5 | 2.5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Kanjinti | between 1 February 2025 and 31 March 2025—0 months stock by reference to usual demand |

10 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | 6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Valproic acid | Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL | Oral | Epilim Liquid | (a) between 1 February 2025 and 31 March 2025—89,358 packs of a pack quantity of 1 (b) between 1 April 2025 and 30 September 2025—91,362 packs of a pack quantity of 1 (c) after 30 September 2025—6 months stock by reference to usual PBS demand |

Schedule 2—Amendments commencing 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Clarithromycin | Powder for oral liquid 250 mg per 5 mL, 50 mL | Oral | Klacid | (a) between 1 April 2025 and 30 September 2025—17,180 packs of a pack quantity of 1 (b) after 30 September 2025—4 months stock by reference to usual PBS demand |

2 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | 4 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | (a) between 1 April 2025 and 30 September 2025—1,228 packs of a pack quantity of 1 (b) after 30 September 2025—4 months stock by reference to usual PBS demand |

3 Schedule 1 (table)

After:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxazepam | Tablet 30 mg | Oral | Murelax | 5 months stock by reference to usual demand |

insert:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Oxybutynin | Transdermal patches 36 mg, 8 | Transdermal | Oxytrol | 6 months stock by reference to usual PBS demand |

Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the *National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024* – 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual | Nitrolingual Pumpspray | 6 months stock by reference to usual PBS demand |

substitute:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual | Nitrolingual Pumpspray | (a) between 1 April 2025 and 30 September 2025—162,432 packs of a pack quantity of 1 (b) after 30 September 2025—6 months stock by reference to usual PBS demand |